Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AEON Biopharma, Inc.AEON · Entity 7859 | Director | June 17, 2026 | June 22, 2026 |
| LENZ Therapeutics, Inc.LENZ · Entity 6475 | Director | June 15, 2026 | June 16, 2026 |
| RxSight, Inc.RXST · Entity 1226 | See remarks | April 14, 2025 | April 16, 2025 |
| Venus Concept Inc.HAIR · Entity 55304 | Director | June 13, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AEON Biopharma, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 258,705 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 222,684 · Balance 258,705 F1: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
LENZ Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.63 · Expires 2036-06-15 | Direct | 22,100 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 22,100 · Balance 22,100 F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
RxSight, Inc.
Report date April 14, 2025 · Filed April 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,354 |
Reported balance
After 2025-04-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-04-14 · Exercise / conversion · Acquired 7,792 · Balance 38,354 F1: Includes 119 shares of Common Stock acquired October 31, 2024 under the Issuer's 2021 Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2025-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-14 · Exercise / conversion · Disposed 6,405 · Balance 0 F2: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2027-03-13 | Direct | 0 |
Reported balance
After 2025-04-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-14 · Exercise / conversion · Disposed 1,387 · Balance 0 F2: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 119 shares of Common Stock acquired October 31, 2024 under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended.
Venus Concept Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2028-06-13 | Direct | 13,708 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 13,708 · Balance 13,708 F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 22:22 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 222,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076515 · tm2618486-5_4seq1.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,705 F1 · security: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date. F1 · price: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 00:18 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 22,100 | $0.00 Strike: $6.63 | $0.00 |
DisclosureSEC source: 0001297491-26-000001 · wk-form4_1781569084.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2036-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000045 · wk-form4_1749678366.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:04 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantRestricted Stock Units · Derivative | 308,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000141 · form4.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,641 Underlying: Class A Common Stock · 308,641 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date. F2 · derivative.exercise_date: 100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025. F2 · derivative.expiration_date: 100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:57 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 1,387 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-25-054439 · ownership.xml · derivative · entry 3 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,387 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:57 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 6,405 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-25-054439 · ownership.xml · derivative · entry 2 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,405 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:57 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 7,792 | $4.34 | $33,806.37 |
DisclosureSEC source: 0000950170-25-054439 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 119 shares of Common Stock acquired October 31, 2024 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 01:04 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $28.21 | $0.00 |
DisclosureSEC source: 0000950170-25-029396 · ownership.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-02-26 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:11 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111461 · ownership.xml · derivative · entry 5 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,367 Underlying: Common Stock · 15,000 shares Expires 2031-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:11 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 278 | $49.45 | $13,747.10 |
DisclosureSEC source: 0000950170-24-111461 · ownership.xml · nonDerivative · entry 4 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,443 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:11 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 9,521 | $48.69 | $463,560.35 |
DisclosureSEC source: 0000950170-24-111461 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,721 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 9,521 shares sold in the price range of $48.375 to $49.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:11 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,201 | $47.96 | $249,422.28 |
DisclosureSEC source: 0000950170-24-111461 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,242 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 5,201 shares sold in the price range of $47.36 to $48.29 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:11 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 15,000 | $16.00 | $240,000.00 |
DisclosureSEC source: 0000950170-24-111461 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2024 Filed Sep 5, 2024 01:51 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantStock Option · Derivative | 96,210 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001104659-24-097060 · tm2423415-8_4seq1.xml · derivative · entry 2 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,210 Underlying: Class A Common Stock · 96,210 shares Expires 2034-08-30 F2 · shares: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. F2 · derivative.exercise_date: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 5, 2024 01:51 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 36,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097060 · tm2423415-8_4seq1.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,021 F1 · price: Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:12 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.24 | $0.00 |
DisclosureSEC source: 0000950170-24-093972 · ownership.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 7, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 00:15 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,270 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-24-084038 · ownership.xml · derivative · entry 3 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,387 Underlying: Common Stock · 5,270 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. F1 · balance_after: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 00:15 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 11,235 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-24-084038 · ownership.xml · derivative · entry 2 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,405 Underlying: Common Stock · 11,235 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. F1 · balance_after: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 00:15 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 16,505 | $4.34 | $71,631.70 |
DisclosureSEC source: 0000950170-24-084038 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · derivative · entry 6 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,805 Underlying: Common Stock · 10,000 shares Expires 2031-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 22, 2021. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,803 | $59.56 | $107,394.07 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · nonDerivative · entry 5 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F6 · price: Represents the weighted average share price of an aggregate total of 1,803 shares sold in the price range of $59.10 to $59.67 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 6,599 | $58.55 | $386,366.17 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · nonDerivative · entry 4 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,803 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 6,599 shares sold in the price range of $58.07 to $59.0117 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,854 | $59.48 | $110,270.36 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,938 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 1,854 shares sold in the price range of $59.25 to $59.725 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 8,146 | $58.41 | $475,785.05 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,792 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 8,146 shares sold in the price range of $58.205 to $58.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,000 | $15.60 | $155,983.00 |
DisclosureSEC source: 0000950170-24-080522 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:58 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000950170-24-052283 · ownership.xml · derivative · entry 5 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,805 Underlying: Common Stock · 10,000 shares Expires 2031-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 22, 2021. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:58 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 380 | $53.04 | $20,154.21 |
DisclosureSEC source: 0000950170-24-052283 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,938 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 380 shares sold in the price range of $53.00 to $53.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:58 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 9,620 | $52.68 | $506,758.51 |
DisclosureSEC source: 0000950170-24-052283 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,318 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 9,620 shares sold in the price range of $52.00 to $52.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:58 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,247 | $15.60 | $159,835.78 |
DisclosureSEC source: 0000950170-24-052283 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 247 shares of Common Stock acquired April 30, 2024 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 543 | $51.50 | $27,964.50 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 6 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 8,402 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 200 | $50.37 | $10,074.00 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 5 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 8,945 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 662 | $50.24 | $33,257.69 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 4 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 9,145 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F6 · price: Represents the weighted average share price of an aggregate total of 662 shares sold in the price range of $50.2066 to $50.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 8,938 | $49.81 | $445,225.02 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 9,807 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 8,938 shares sold in the price range of $49.20 to $50.1963 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 800 | $50.27 | $40,218.00 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 18,745 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 800 shares sold in the price range of $50.22 to $50.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 8,857 | $49.81 | $441,207.03 |
DisclosureSEC source: 0000950170-24-040174 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 19,545 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 8,857 shares sold in the price range of $49.20 to $50.18 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Shelley B. Thunen Revocable Family Trust, as Amended, for which the Reporting Person serves as trustee. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:44 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000029 · wk-form4_1711413836.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 23:52 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantStock Option · Derivative | 16,260 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001104659-24-037441 · tm249503-7_4seq1.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2034-03-18 F1 · shares: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company. F1 · derivative.exercise_date: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:25 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 92,200 | $0.00 Strike: $56.07 | $0.00 |
DisclosureSEC source: 0000950170-24-027183 · ownership.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,200 Underlying: Common Stock · 92,200 shares Expires 2034-03-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000950170-24-025874 · ownership.xml · derivative · entry 6 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,805 Underlying: Common Stock · 10,000 shares Expires 2031-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 22, 2021. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 2,473 | $57.03 | $141,041.87 |
DisclosureSEC source: 0000950170-24-025874 · ownership.xml · nonDerivative · entry 4 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,691 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 2,473 shares sold in the price range of $56.745 to $57.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 6,361 | $56.38 | $358,617.91 |
DisclosureSEC source: 0000950170-24-025874 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,164 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 6,361 shares sold in the price range of $55.73 to $56.72 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,166 | $54.95 | $64,065.87 |
DisclosureSEC source: 0000950170-24-025874 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,525 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 1,166 shares sold in the price range of $54.67 to $55.66 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,000 | $15.60 | $155,983.00 |
DisclosureSEC source: 0000950170-24-025874 · ownership.xml · nonDerivative · entry 1 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 15,875 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · derivative · entry 9 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 15,875 shares Expires 2033-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 15,875 | $47.47 | $753,573.55 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · nonDerivative · entry 5 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,691 F2 · price: Represents the weighted average share price of an aggregate total of 15,875 shares sold in the price range of $47.16 to $47.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 15,875 | $14.95 | $237,331.25 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · nonDerivative · entry 4 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 9,125 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · derivative · entry 8 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,875 Underlying: Common Stock · 9,125 shares Expires 2033-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 6,900 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · derivative · entry 7 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,640 Underlying: Common Stock · 6,900 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. F4 · balance_after: Shares issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 9,125 | $47.02 | $429,086.70 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · nonDerivative · entry 3 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,691 F1 · price: Represents the weighted average share price of an aggregate total of 9,125 shares sold in the price range of $47.00 to $47.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 22:18 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 9,125 | $14.95 | $136,418.75 |
DisclosureSEC source: 0000950170-24-012317 · ownership.xml · nonDerivative · entry 2 Thunen Shelley B · CIK 0001297491 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.